Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?
03:30pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?
12:48pm, Wednesday, 07'th Sep 2022
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
09:03am, Thursday, 01'st Sep 2022
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference
Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC
04:17pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.
Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade
01:55pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock?
04:00pm, Friday, 26'th Aug 2022 Zacks Investment Research
Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Friday, 26'th Aug 2022
Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
03:06pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
12:47pm, Tuesday, 09'th Aug 2022
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees
12:33pm, Tuesday, 09'th Aug 2022 Benzinga
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday.
ACADIA Pharmaceuticals posted a quarterly loss of $0.21 per share on sales
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
10:44am, Tuesday, 09'th Aug 2022 Benzinga
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
09:35pm, Monday, 08'th Aug 2022 Zacks Investment Research
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2022 Results - Earnings Call Transcript
09:05pm, Monday, 08'th Aug 2022
ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Kathie Bishop - SVP and Head, Rare Disease & External Innovation Srdjan Stan
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
02:10pm, Monday, 08'th Aug 2022 Benzinga
Upgrades
For iRobot Corp (NASDAQ:IRBT), JP Morgan upgraded the previous rating of Underweight to Neutral. In the second quarter, iRobot showed an EPS of $0.35, compared to $0.27 from the year-ago qua
